The center will leverage what the company has learned from supporting numerous client cell and gene therapy programs, including the first gene therapy approved in Europe, Glybera. Through the center, Veristat will offer tailored solutions across the entire clinical development pathway. The center will serve as a mechanism for Veristat to share insights, successful strategies, and best practices with customers.

Services offered through the center include accelerated pathways and special designations for therapeutics, review of operational protocols, novel implementation strategies, expertise in logistics and handling of live cellular material, bespoke regulatory strategies, and long-term follow-up strategies to meet global regulatory requirements.

MilliporeSigma holds topping-out ceremony for new membrane plant
MilliporeSigma celebrated the topping out of its new membrane production plant in Darmstadt, Germany, with a ceremony on October 8.

Is 'bespoke' therapy the future of genomic medicine?
Gene therapies hold extremely exciting promise for meeting the unmet needs of many individuals with genetic diseases, as discussed in a session of the...

FDA debuts website for patient-reported cancer outcomes
The U.S. Food and Drug Administration (FDA) has unveiled Project Patient Voice, a new pilot program for communicating patient-reported outcomes from cancer...